{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:26Z","timestamp":1790772146720,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>First\u2010generation antihistamines are considered driving\u2010impairing medicines (DIM), while second\u2010 and third\u2010generation antihistamines are relatively safe for driving.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to know the trend of consumption of antihistamines and other DIMs in Spain between 2015 and 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a population\u2010based registry study. The population distribution by age and gender has been taken into account, as well the treatment duration with these medicines and the concomitant use of other DIMs. Adjusted consumption for licensed drivers is also presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2015 and 2019, antihistamines were dispensed to 12.1% of the population and 9.25% of drivers. Oral antihistamines are the most consumed with 85.83%, and generally more used by women than men. Regardless of systemic antihistamines, the second\u2010generation were the most consumed (8.9%) followed by the third\u2010generation (2.07%) and the first\u2010generation (0.61%). Subacute use was predominant in second \u2010generation antihistamines (4.96%) and third\u2010generation (1.26%), while acute use was predominant in third\u2010generation antihistamines. On the other hand, only 0.36% of the population consumed antihistamines daily. The concomitant use of antihistamines with other DIMS was considerable, especially anxiolytics, opioids, other analgesics and antipyretics and antidepressants. The results in drivers were similar than in the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of antihistamines has increased in recent years, however, in Spain, the use of less sedatives predominates, which is safe for driving. Finally, it is important to consider that concomitant use with other DIMs was frequent, which may affect the fitness to drive.<\/jats:p><\/jats:sec>","DOI":"10.1111\/fcp.12680","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T07:14:22Z","timestamp":1617952462000},"page":"1168-1178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in the use of antihistamines with reference to drivers between 2015 and 2019: A population\u2010based registry analysis"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-934X","authenticated-orcid":false,"given":"Eduardo","family":"Guti\u00e9rrez\u2010Abej\u00f3n","sequence":"first","affiliation":[{"name":"Pharmacological Big Data Laboratory, Pharmacology and Therapeutics Faculty of Medicine University of Valladolid  Valladolid Spain"},{"name":"Technical Direction of Pharmaceutical Assistance Gerencia Regional de Salud de Castilla y Le\u00f3n  Valladolid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Herrera\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, Pharmacology and Therapeutics Faculty of Medicine University of Valladolid  Valladolid Spain"},{"name":"Hospital Virgen de la Concha\u2014Sanidad de Castilla y Le\u00f3n  Zamora Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Pharmacological Big Data Laboratory, Pharmacology and Therapeutics Faculty of Medicine University of Valladolid  Valladolid Spain"},{"name":"CEIm Hospital Cl\u00ednico Universitario de Valladolid\u2014Sanidad de Castilla y Le\u00f3n  Valladolid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-012-9689-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-0010-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-199903000-00005"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13307"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13701"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0375-9"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9149-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2013.861597"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02325.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014520882"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb01140.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-015-0002-6"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2524"},{"key":"e_1_2_9_15_1","unstructured":"OTC drugs: global market share by therapeutic area 2016. Statista.https:\/\/www.statista.com\/statistics\/748198\/global\u2010market\u2010share\u2010of\u2010otc\u2010drugs\u2010by\u2010therapeutic\u2010area\/. Accessed September 8 2020."},{"key":"e_1_2_9_16_1","unstructured":"Antihistamines: Leading Labs by Units Sold 2018. Statista.https:\/\/es.statista.com\/estadisticas\/791864\/unidades\u2010de\u2010antihistaminicos\u2010vendidas\u2010por\u2010laboratorio\u2010en\u2010espana\/. Accessed May 20 2020."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017618"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00408"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000263"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122148"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13040061"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13080165"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_2_9_24_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology \u2013 ATC\/DDD Index 2020.https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed February 23 2020."},{"key":"e_1_2_9_25_1","unstructured":"CONCYLIA.Sistema de Informaci\u00f3n de Farmacia. Gerencia Regional de Salud de Castilla y Le\u00f3n.Valladolid Spain:Junta de Castilla y Le\u00f3n.http:\/\/www.saludcastillayleon.es\/portalmedicamento\/es\/indicadoresinformes\/CONCYLIA. Accessed March 3 2021."},{"key":"e_1_2_9_26_1","unstructured":"Junta de Castilla y Le\u00f3n. IV Plan de Salud de Castilla y Le\u00f3n: Perspectiva 2020\/[IV Health Plan of Castilla y Le\u00f3n: 2020 Perspective].http:\/\/www.jcyl.es\/junta\/cp\/Analisis_situacion_IVPdS.pdf. Accessed March 29 2021."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1763"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000366"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.01874.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80137-6"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1559827615609050"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2017.05.030"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:56:47Z","timestamp":1693209407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/fcp.12680"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12680","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"2021-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}